Time-to-therapy discontinuation in patients newly diagnosed with schizophrenia initiated on long-acting injectable versus oral dopamine receptor blocking agents.
antipsychotic
discontinuation
long-acting injectable
oral
readmission
Journal
Early intervention in psychiatry
ISSN: 1751-7893
Titre abrégé: Early Interv Psychiatry
Pays: Australia
ID NLM: 101320027
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
revised:
06
12
2022
received:
28
06
2022
accepted:
01
01
2023
medline:
7
9
2023
pubmed:
14
1
2023
entrez:
13
1
2023
Statut:
ppublish
Résumé
The purpose of this project is to assess the time-to-therapy discontinuation and hospital readmission rate among patients newly diagnosed with schizophrenia who are prescribed long-acting injectable versus oral dopamine receptor blocking agents. A retrospective review of medical records was performed for adult patients admitted to an 80-bed inpatient behavioural health facility with a new diagnosis of schizophrenia. The primary outcome studied was time to therapy discontinuation within 1 year of discharge, while secondary outcomes assessed were time-to-therapy discontinuation within 90 days and readmission rate at 30-days, 6 months, and 1 year. Multivariate Cox proportional hazard and linear regression modelling were used for statistical analysis. A total of 425 patients were included in the analysis, with 66.4% (n = 282) discharged on oral and 33.6% (n = 143) on long-acting injectable dopamine receptor blocking agents. At 1 year post-discharge, the rates of discontinuation were 49.7% for those prescribed long-acting injectable and 55.7% for those prescribed oral formulations (adjusted hazard ratio = 0.54, p = .012). There was no statistically significant difference in readmission rate between the patients prescribed long-acting injectable and oral dopamine receptor blocking agents at any timepoint tested. The use of long-acting injectable dopamine receptor blocking agents was associated with longer time-to-discontinuation compared to oral agents when prescribed to patients newly diagnosed with schizophrenia in the inpatient setting. However, this was not associated with significant reductions in rehospitalization, calling into question the clinical impact. Future studies will seek to confirm these findings using a prospective study design.
Substances chimiques
Antipsychotic Agents
0
Receptors, Dopamine
0
Delayed-Action Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
921-928Informations de copyright
© 2023 The Authors. Early Intervention in Psychiatry published by John Wiley & Sons Australia, Ltd.
Références
Abdel-Baki, A., Medrano, S., Maranda, C., Ladouceur, M., Tahir, R., Stip, E., & Potvin, S. (2020). Impact of early use of long-acting injectable antipsychotics on psychotic relapses and hospitalizations in first-episode psychosis. International Clinical Psychopharmacology, 35(4), 221-228. https://doi.org/10.1097/yic.0000000000000310
Barrio, P., Batalla, A., Castellví, P., Hidalgo, D., García, M., Ortiz, A., Grande, I., Pons, A., & Parellada, E. (2013). Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: A case-control study. International Clinical Psychopharmacology, 28(4), 164-170. https://doi.org/10.1097/YIC.0b013e3283611cc3
Biagi, E., Capuzzi, E., Colmegna, F., Mascarini, A., Brambilla, G., Ornaghi, A., Santambrogio, J., & Clerici, M. (2017). Long-acting injectable antipsychotics in schizophrenia: Literature review and practical perspective, with a focus on aripiprazole once-monthly. Advances in Therapy, 34(5), 1036-1048. https://doi.org/10.1007/s12325-017-0507-x
Chen, S., Collins, A., & Kidd, S. A. (2018). Thirty-day and 5-year readmissions following first psychiatric hospitalization: A system-level study of Ontario's psychiatric care. Canadian Journal of Psychiatry, 63(6), 410-415. https://doi.org/10.1177/0706743717751667
Corigliano, V., Comparelli, A., Mancinelli, I., Montalbani, B., Lamis, D. A., De Carolis, A., Erbuto, D., Girardi, P., & Pompili, M. (2018). Long-acting injectable second-generation antipsychotics improve negative symptoms and suicidal ideation in recent diagnosed schizophrenia patients: A 1-year follow-up pilot study. Schizophrenia Research and Treatment, 2018, 4834135-4834137. https://doi.org/10.1155/2018/4834135
Correll, C. U., Galling, B., Pawar, A., Krivko, A., Bonetto, C., Ruggeri, M., Craig, T. J., Nordentoft, M., Srihari, V. H., Guloksuz, S., & Hui, C. L. (2018). Comparison of early intervention services vs treatment as usual for early-phase psychosis: A systematic review, meta-analysis, and meta-regression. JAMA Psychiatry, 75(6), 555-565. https://doi.org/10.1001/jamapsychiatry.2018.0623
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002). A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New England Journal of Medicine, 346(1), 16-22. https://doi.org/10.1056/NEJMoa002028
Danivas, V., & Venkatasubramanian, G. (2013). Current perspectives on chlorpromazine equivalents: Comparing apples and oranges! Indian Journal of Psychiatry, 55(2), 207-208. https://doi.org/10.4103/0019-5545.111475
Doshi, J. A., Pettit, A. R., Stoddard, J. J., Zummo, J., & Marcus, S. C. (2015). Concurrent Oral antipsychotic drug use among schizophrenia patients initiated on long-acting injectable antipsychotics post-hospital discharge. Journal of Clinical Psychopharmacology, 35(4), 442-446. https://doi.org/10.1097/jcp.0000000000000353
Emsley, R., Chiliza, B., Asmal, L., Mashile, M., & Fusar-Poli, P. (2013). Long-acting injectable antipsychotics in early psychosis: A literature review. Early Intervention in Psychiatry, 7(3), 247-254. https://doi.org/10.1111/eip.12027
FDA. (2013). Approves once-monthly ABILIFY MAINTENA™ (Aripiprazole) for extended-release injectable suspension for the treatment of schizophrenia. Retrieved from https://www.otsuka.co.jp/en/company/newsreleases/2013/20130301_1.html
Giordano, G., Tomassini, L., Cuomo, I., Amici, E., Perrini, F., Callovini, G., Carannante, A., Kotzalidis, G. D., & De Filippis, S. (2019). Aripiprazole long-acting injection during first episode schizophrenia-an exploratory analysis. Frontiers in Psychiatry, 10, 935. https://doi.org/10.3389/fpsyt.2019.00935
Gómez-Revuelta, M., Pelayo-Terán, J. M., Juncal-Ruiz, M., Vázquez-Bourgon, J., Suárez-Pinilla, P., Romero-Jiménez, R., Setién Suero, E., Ayesa-Arriola, R., & Crespo-Facorro, B. (2020). Antipsychotic treatment effectiveness in first episode of psychosis: PAFIP 3-year follow-up randomized clinical trials comparing haloperidol, olanzapine, risperidone, aripiprazole, quetiapine, and ziprasidone. International Journal of Neuropsychopharmacology, 23(4), 217-229. https://doi.org/10.1093/ijnp/pyaa004
Haddad, P. M., Brain, C., & Scott, J. (2014). Nonadherence with antipsychotic medication in schizophrenia: Challenges and management strategies. Patient Related Outcome Measures, 5, 43-62. https://doi.org/10.2147/prom.S42735
Haddad, P. M., Taylor, M., & Niaz, O. S. (2009). First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. The British Journal of Psychiatry. Supplement, 52, S20-S28. https://doi.org/10.1192/bjp.195.52.s20
Heslin, K. C., & Weiss, A. J. (2015). Hospital readmissions involving psychiatric disorders, 2012. Retrieved from https://www.hcup-us.ahrq.gov/reports/statbriefs/sb189-Hospital-Readmissions-Psychiatric-Disorders-2012.pdf
Horvitz-Lennon, M., Predmore, Z., Orr, P., Hanson, M., Hillestad, R., Durkin, M., Kim, E., & Mattke, S. (2019). Simulated long-term outcomes of early use of long-acting injectable antipsychotics in early schizophrenia. Early Intervention in Psychiatry, 13(6), 1357-1365. https://doi.org/10.1111/eip.12770
Huang, C. Y., Fang, S. C., & Shao, Y. J. (2021). Comparison of long-acting injectable antipsychotics with Oral antipsychotics and suicide and all-cause mortality in patients with newly diagnosed schizophrenia. JAMA Network Open, 4(5), e218810. https://doi.org/10.1001/jamanetworkopen.2021.8810
Huhn, M., Nikolakopoulou, A., Schneider-Thoma, J., Krause, M., Samara, M., Peter, N., Arndt, T., Bäckers, L., Rothe, P., Cipriani, A., & Davis, J. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet, 394, 939-951. https://doi.org/10.1016/s0140-6736(19)31135-3
Hung, Y. Y., Chan, H. Y., & Pan, Y. J. (2017). Risk factors for readmission in schizophrenia patients following involuntary admission. PLoS One, 12(10), e0186768. https://doi.org/10.1371/journal.pone.0186768
Kane, J. M., Schooler, N. R., Marcy, P., Correll, C. U., Achtyes, E. D., Gibbons, R. D., & Robinson, D. G. (2020). Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: A randomized clinical trial. JAMA Psychiatry, 77(12), 1217-1224. https://doi.org/10.1001/jamapsychiatry.2020.2076
Kardas, P. (2011). Prevalence of non-adherence to medication among patients treated for selected chronic conditions. Polski Merkuriusz Lekarski, 31(184), 215-220.
Keating, D., McWilliams, S., Boland, F., Doyle, R., Behan, C., Strawbridge, J., & Clarke, M. (2021). Prescribing pattern of antipsychotic medication for first-episode psychosis: A retrospective cohort study. BMJ Open, 11(1), e040387. https://doi.org/10.1136/bmjopen-2020-040387
Kim, B., Lee, S.-H., Yang, Y. K., Park, J.-I., & Chung, Y.-C. (2012). Long-acting injectable antipsychotics for first-episode schizophrenia: The pros and cons. Schizophrenia Research and Treatment, 2012, 560836. https://doi.org/10.1155/2012/560836
Kim, H. O., Seo, G. H., & Lee, B. C. (2020). Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia. Annals of General Psychiatry, 19(1), 1. https://doi.org/10.1186/s12991-019-0254-2
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021). Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: A systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry, 8(5), 387-404. https://doi.org/10.1016/s2215-0366(21)00039-0
Kishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018). Effectiveness of long-acting injectable vs Oral antipsychotics in patients with schizophrenia: A meta-analysis of prospective and retrospective cohort studies. Schizophrenia Bulletin, 44(3), 603-619. https://doi.org/10.1093/schbul/sbx090
Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2014). Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophrenia Bulletin, 40(1), 192-213. https://doi.org/10.1093/schbul/sbs150
Kondrátová, L., & Mladá, K. (2020). S129. Rehospitalization rate in people with first-episode psychosis IN The Czech Republic: A register-based study. Schizophrenia Bulletin, 46(Suppl 1), S84.
Lee, S., & Schwartz, S. (2021). Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: A systematic review and meta-analysis of cohort studies. Psychiatry Research, 306, 114277. https://doi.org/10.1016/j.psychres.2021.114277
Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011). Oral versus depot antipsychotic drugs for schizophrenia - A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Research, 127(1-3), 83-92. https://doi.org/10.1016/j.schres.2010.11.020
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. The Lancet, 379(9831), 2063-2071. https://doi.org/10.1016/s0140-6736(12)60239-6
Lian, L., Kim, D. D., Procyshyn, R. M., Cázares, D., Honer, W. G., & Barr, A. M. (2022). Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. PLoS One, 17(4), e0267808. https://doi.org/10.1371/journal.pone.0267808
Lian, L., Kim, D. D., Procyshyn, R. M., Fredrikson, D. H., Cázares, D., Honer, W. G., & Barr, A. M. (2021). Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis. Early Intervention in Psychiatry, 16, 589-599. https://doi.org/10.1111/eip.13202
Lieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., & Wei, H. (2003). Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry, 160(8), 1396-1404. https://doi.org/10.1176/appi.ajp.160.8.1396
Preferred Drug List. (2022). Retrieved from. https://medicaid.ncdhhs.gov/preferred-drug-list
Mahlich, J., Olbrich, K., Wilk, A., Wimmer, A., & Wolff-Menzler, C. (2021). Time to treatment discontinuation in German patients with schizophrenia: Long-acting injectables versus Oral antipsychotics. Clinical Drug Investigation, 41(1), 99-113. https://doi.org/10.1007/s40261-020-00990-8
Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J., & Doshi, J. A. (2015). Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge. Journal of Managed Care & Specialty Pharmacy, 21(9), 754-768. https://doi.org/10.18553/jmcp.2015.21.9.754
Marshall, M., Lewis, S., Lockwood, A., Drake, R., Jones, P., & Croudace, T. (2005). Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: A systematic review. Archives of General Psychiatry, 62(9), 975-983. https://doi.org/10.1001/archpsyc.62.9.975
McDonagh, M. S., Dana, T., Selph, S., Devine, E. B., Cantor, A., Bougatsos, C., Blazina, I., Grusing, S., Fu, R., Kopelovich, S. L., Monroe-DeVita, M., & Haupt, D. W. (2017). Treatments for schizophrenia in adults: A systematic review. Comparative effectiveness review no. 198. (prepared by the Pacific northwest evidence-based practice center under contract no. 290-2015-00009-I.). Retrieved from Rockville, MD: www.effectivehealthcare.ahrq.gov/reports/final.cfm
Medrano, S., Abdel-Baki, A., Stip, E., & Potvin, S. (2018). Three-year naturalistic study on early use of long-acting injectable antipsychotics In first episode psychosis. Psychopharmacology Bulletin, 48(4), 25-61.
Mohamed, S., Rosenheck, R., Harpaz-Rotem, I., Leslie, D., & Sernyak, M. J. (2009). Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. The Psychiatric Quarterly, 80(4), 241-249. https://doi.org/10.1007/s11126-009-9111-9
Montemagni, C., Del Favero, E., Cocuzza, E., Vischia, F., & Rocca, P. (2022). Effect of long-acting injectable antipsychotics on hospitalizations and global functioning in schizophrenia: A naturalistic mirror-image study. Therapeutic Advances in Psychopharmacology, 12, 20451253221122526. https://doi.org/10.1177/20451253221122526
Munday, J., Greene, M., Chang, E., Hartry, A., Yan, T., & Broder, M. S. (2019). Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: Real-world evidence from US claims data. Current Medical Research and Opinion, 35(7), 1231-1239. https://doi.org/10.1080/03007995.2019.1571295
Ochoa, S., Usall, J., Cobo, J., Labad, X., & Kulkarni, J. (2012). Gender differences in schizophrenia and first-episode psychosis: A comprehensive literature review. Schizophrenia Research and Treatment, 2012, 916198. https://doi.org/10.1155/2012/916198
Parellada, E., & Bioque, M. (2016). Barriers to the use of long-acting injectable antipsychotics in the Management of Schizophrenia. CNS Drugs, 30(8), 689-701. https://doi.org/10.1007/s40263-016-0350-7
Patel, M. X., Arista, I. A., Taylor, M., & Barnes, T. R. (2013). How to compare doses of different antipsychotics: A systematic review of methods. Schizophrenia Research, 149(1-3), 141-148. https://doi.org/10.1016/j.schres.2013.06.030
Patel, M. X., Taylor, M., & David, A. S. (2009). Antipsychotic long-acting injections: Mind the gap. The British Journal of Psychiatry. Supplement, 52, S1-S4. https://doi.org/10.1192/bjp.195.52.s1
Robinson, D., Woerner, M. G., Alvir, J. M., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., & Lieberman, J. A. (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 56(3), 241-247. https://doi.org/10.1001/archpsyc.56.3.241
Rubio, J. M., Taipale, H., Tanskanen, A., Correll, C. U., Kane, J. M., & Tiihonen, J. (2021). Long-term continuity of antipsychotic treatment for schizophrenia: A Nationwide study. Schizophrenia Bulletin, 47(6), 1611-1620. https://doi.org/10.1093/schbul/sbab063
Salgueiro, M., & Segarra, R. (2019). Long-acting injectable second-generation antipsychotics in first-episode psychosis: A narrative review. International Clinical Psychopharmacology, 34(2), 51-56. https://doi.org/10.1097/yic.0000000000000249
Sanger, T. M., Lieberman, J. A., Tohen, M., Grundy, S., Beasley, C., Jr., & Tollefson, G. D. (1999). Olanzapine versus haloperidol treatment in first-episode psychosis. American Journal of Psychiatry, 156(1), 79-87. https://doi.org/10.1176/ajp.156.1.79
Schizophrenia. (2022). Retrieved from https://www.nami.org/About-Mental-Illness/Mental-Health-Conditions/Schizophrenia
Subotnik, K. L., Casaus, L. R., Ventura, J., Luo, J. S., Hellemann, G. S., Gretchen-Doorly, D., Marder, S., & Nuechterlein, K. H. (2015). Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A Randomized Clinical Trial. JAMA Psychiatry, 72(8), 822-829. https://doi.org/10.1001/jamapsychiatry.2015.0270
Taipale, H., Mehtälä, J., Tanskanen, A., & Tiihonen, J. (2018). Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia-a Nationwide study with 20-year follow-up. Schizophrenia Bulletin, 44(6), 1381-1387. https://doi.org/10.1093/schbul/sbx176
Takacs, P., Czobor, P., Feher, L., Gimesi-Orszagh, J., Fadgyas-Freyler, P., Bacskai, M., Rakonczai, P., Borsi, A., Hegyi, R., Németh, T., & Sermon, J. (2019). Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary. PLoS One, 14(6), e0218071. https://doi.org/10.1371/journal.pone.0218071 eCollection 2019.
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011). A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. The American Journal of Psychiatry, 168(6), 603-609. https://doi.org/10.1176/appi.ajp.2011.10081224
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., & Taipale, H. (2017). Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry, 74(7), 686-693. https://doi.org/10.1001/jamapsychiatry.2017.1322
Tiihonen, J., Tanskanen, A., & Taipale, H. (2018). 20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia. The American Journal of Psychiatry, 175(8), 765-773. https://doi.org/10.1176/appi.ajp.2018.17091001
Tiihonen, J., Wahlbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J. P., Volavka, J., & Haukka, J. (2006). Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: Observational follow-up study. BMJ, 333(7561), 224. https://doi.org/10.1136/bmj.38881.382755.2F
Titus-Lay, E. N., Ansara, E. D., Isaacs, A. N., & Ott, C. A. (2018). Evaluation of adherence and persistence with oral versus long-acting injectable antipsychotics in patients with early psychosis. Clinical Practice and Epidemiology, 8(2), 56-62. https://doi.org/10.9740/mhc.2018.03.056
Wei, Y., Yan, V. K. C., Kang, W., Wong, I. C. K., Castle, D. J., Gao, L., Chui, C. S., Man, K. K., Hayes, J. F., Chang, W. C., & Chan, E. W. (2022). Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among People with schizophrenia. JAMA Network Open, 5(7), e2224163. https://doi.org/10.1001/jamanetworkopen.2022.24163
Weiden, P. J., Schooler, N. R., Weedon, J. C., Elmouchtari, A., & Sunakawa-McMillan, A. (2012). Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: A randomized effectiveness study. The Journal of Clinical Psychiatry, 73(9), 1224-1233. https://doi.org/10.4088/JCP.11m06905
Zhornitsky, S., & Stip, E. (2012). Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: A systematic review. Schizophrenia Research and Treatment, 2012, 407171. https://doi.org/10.1155/2012/407171
Zhu, Y., Krause, M., Huhn, M., Rothe, P., Schneider-Thoma, J., Chaimani, A., Li, C., Davis, J. M., & Leucht, S. (2017). Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: A systematic review with pairwise and network meta-analyses. Lancet Psychiatry, 4(9), 694-705. https://doi.org/10.1016/s2215-0366(17)30270-5